<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Gastro Hep Adv</journal-id><journal-id journal-id-type="iso-abbrev">Gastro Hep Adv</journal-id><journal-title-group><journal-title>Gastro Hep Advances</journal-title></journal-title-group><issn pub-type="epub">2772-5723</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11785905</article-id><article-id pub-id-type="pii">S2772-5723(24)00133-X</article-id><article-id pub-id-type="doi">10.1016/j.gastha.2024.07.020</article-id><article-id pub-id-type="publisher-id">100539</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Letter</subject></subj-group></article-categories><title-group><article-title>Shotgun Metagenomics Reveals <italic>Bacteroides stercoris</italic> as a Fecal Biomarker Depleted in Late-Stage Hepatocellular Carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Esparteiro</surname><given-names>Damien</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Fouquet</surname><given-names>Gr&#x000e9;gory</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Courtois</surname><given-names>Ano&#x000ef;sia</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Naassila</surname><given-names>Micka&#x000eb;l</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Nguyen-Khac</surname><given-names>Eric</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Marcq</surname><given-names>Ingrid</given-names></name><email>ingrid.marcq@u-picardie.fr</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1"><label>1</label>GRAP INSERM U1247, Amiens, France</aff><aff id="aff2"><label>2</label>Service d&#x02019;H&#x000e9;pato-Gastro-Ent&#x000e9;rologie, CHU d&#x02019;Amiens, Amiens, France</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label><bold>Correspondence:</bold> Address correspondence to: Ingrid Marcq, PhD, Groupe de Recherche sur l'Alcool et les Pharmacod&#x000e9;pendances, Universit&#x000e9; de Picardie Jules Verne, 30 Avenue de la Croix Jourdain, Amiens 80000, France. <email>ingrid.marcq@u-picardie.fr</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>30</day><month>8</month><year>2024</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>30</day><month>8</month><year>2024</year></pub-date><volume>4</volume><issue>1</issue><elocation-id>100539</elocation-id><history><date date-type="received"><day>4</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>7</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions></article-meta><def-list><title>Abbreviations used in this paper</title><def-item><term id="kwrd0010dh">BCLC</term><def><p>Barcelona Clinic Liver Cancer</p></def></def-item><def-item><term id="kwrd0ds010dh">GM</term><def><p>gut microbiota</p></def></def-item><def-item><term id="kwrd00iyt10dh">HCC</term><def><p>hepatocellular carcinoma</p></def></def-item></def-list></front><body><p id="p0010">Simultaneous study of the gut and the liver is promising for a better understanding of hepatic malignancies due to their bidirectional communication through the gut-liver axis. Gut Microbiota (GM), which under normal circumstances contributes to the host homeostasis, may become dysbiotic, which can in turn contribute to liver inflammation.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Prolonged liver inflammation in cirrhotic patients, for example due to gut-liver translocation and/or alcohol exposure, can lead to the development of Hepatocellular Carcinoma (HCC), the most frequent form of primary liver cancer, which is associated with a poor prognosis especially since it is often diagnosed at a stage too advanced to be curable. In this study, we characterized the GM of 51 HCC patients included in the prospective French CHIEF (Cohorte prospective de patients atteints de Carcinome H&#x000e9;patocellulaire en France) cohort using shotgun metagenomics in order to elucidate how the GM changes alongside HCC progression.</p><p id="p0015">Patients were retrospectively selected from the cohort of the Amiens University Hospital based on the availability of their stool samples and the Barcelona Clinic Liver Cancer (BCLC) of the liver biopsy at the inclusion. We regrouped the patients into two groups depending on their BCLC stage; the early-stage group and the late-stage group. 18 and 16 HCC patients with respectively BCLC A and BCLC B stage were included in the early-stage group, and 15 and 2 HCC patients with respectively BCLC C and BCLC D were included in the late-stage group. DNA was extracted from the stool samples (QIAmp Fast DNA Stool Mini Kit, Qiagen) and was then sequenced (NextSeq 550, Illumina). After sequence cleaning, taxonomic assignment was performed using MetaPhlAn 4.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Read counts were analyzed at the species level.</p><p id="p0020">Species richness evaluated using Chao1 index was significantly reduced in late-stage HCC patients (<xref rid="fig1" ref-type="fig">Figure&#x000a0;A</xref>, 120.9 species for early-stage vs 80.2 species for late-stage, <italic>P</italic>&#x000a0;= .005, Welch's t-test). We then tested whether overall GM composition differed between early- and late-stage HCC patients by analyzing beta-diversity using Permutational Multivariate Analysis of Variance (PERMANOVA) of the Bray-Curtis index (<xref rid="fig1" ref-type="fig">Figure&#x000a0;B</xref>). BCLC staging did not significantly explain GM variability (R<sup>2</sup>&#x000a0;= 0.02, <italic>P</italic>&#x000a0;= .289). Thus, in spite of a GM encompassing fewer species for late-grade HCC patients, the GM was overall similar for early- and late-grade HCC, suggesting that the difference in species richness is due to the disappearance of several rare rather than prevalent and abundant species. Then, each species with a prevalence higher than 10% was tested for differential abundance analysis using multivariate linear mixed model with MaAsLin 2<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> adjusting for age, sex, HCC stage, and etiology. While no species was significantly associated with age, sex or etiology, only one species had a significantly different abundance between early- and late-stage HCC patients, <italic>Bacteroides stercoris,</italic> which was depleted in the GM of HCC patients with an advanced stage (Benjamini-Hochberg corrected <italic>P</italic>&#x000a0;= .007). While it is not uncommon in GM analysis to detect significant associations with clinical features, this result is intriguing because of the importance of the difference between early- and late-stage HCC patients, and the fact that no other species was differently abundant. <italic>B.&#x000a0;stercoris</italic> represented a non-negligible fraction of the GM of early-grade patients, accounting on average for 0.7% of their GM (<xref rid="fig1" ref-type="fig">Figure&#x000a0;C</xref>). More strikingly, while <italic>B.&#x000a0;stercoris</italic> was detected in stool samples of 22 (64.7%) early-stage HCC patients, it was detected in stool samples of 1 (5.9%) late-stage HCC patient, with a relative abundance below 0.01% (<xref rid="fig1" ref-type="fig">Figure&#x000a0;D</xref>). Put together, these results suggest that <italic>B.&#x000a0;stercoris</italic> can be used as a novel non-invasive fecal biomarker to evaluate HCC progression.<fig id="fig1"><label>Figure</label><caption><p>Analysis of the GM of HCC patients. 34 patients were classified as early-grade and 17 patients as late-grade. Alpha-diversity was evaluated using Chao1 index, which was significantly reduced in late-grade HCC (120.9 vs 80.2 species, <italic>P</italic>&#x000a0;= .005<italic>,</italic> Welch's t-test (A). However, no difference was found according to a permutational multivariate analysis of variance of the Bray-Curtis beta-diversity metric (B), which suggests that the GM is nonetheless close between early and late-grade HCC. This species was detected in most early-grade HCC patients but only in one late-grade HCC patient (C). Multivariate differential abundance analysis revealed that <italic>Bacteroides stercoris</italic> was significantly enriched in stool samples of early-grade HCC patients (Benjamini-Hochberg corrected <italic>P&#x000a0;=</italic> .007).</p></caption><graphic xlink:href="gr1"/></fig></p><p id="p0025">While past research already characterizing the GM of HCC patients using 16S sequencing did not report <italic>B.&#x000a0;stercoris</italic> disappearance in late-stage HCC, the use of metagenomics allowed a taxonomical resolution at the species level that could not be achieved by others.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> Another metagenomics study reported that this species was depleted in stool samples of colorectal cancer patients,<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> while Zaidi <italic>et&#x000a0;al.</italic> found that <italic>B.&#x000a0;stercoris</italic> was depleted in the circulating microbiota of patients with esophageal adenocarcinoma.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> In contrast, a recent study reported that <italic>B.&#x000a0;stercoris</italic> was significantly enriched in stool samples of patients with esophageal squamous cell carcinoma, a second subtype of esophageal cancer, in comparison with healthy controls.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> Interestingly, an enrichment in the fecal abundance of the same species was detected in patients with advanced predominantly cutaneous melanoma that responded to programmed cell death protein 1 blockade.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> Thus, since <italic>B.&#x000a0;stercoris</italic> isolation from feces was reported in 1986, this species has been associated with digestive cancers in several studies. On the other hand, only one study provides insight into <italic>B.&#x000a0;stercoris</italic> metabolism both in an <italic>in&#x000a0;vitro</italic> and in a preclinical model. Ryu <italic>et&#x000a0;al.</italic> indeed reported that the culture supernatant of a strain of <italic>B.&#x000a0;stercoris</italic> demonstrated an anti-obesity activity <italic>in&#x000a0;vitro</italic> and that the oral administration of this strain to mice on high-fat diet significantly reduced weight gain compared to controls, in spite of identical food intake.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> The link between this study and the recurrent association of <italic>B.&#x000a0;stercoris</italic> with cancers remains unclear.</p><p id="p0030">In summary, we provide in this study evidence that <italic>B.&#x000a0;stercoris</italic> represents a potential novel non-invasive biomarker of HCC progression and that this biomarker deserves further evaluation in other studies using multicentric and independent cohorts. In addition, further research is needed to provide a mechanistic explanation about the depletion of <italic>B.&#x000a0;stercoris</italic> in the GM of late-stage HCC patients, and more generally its possible role in digestive cancers.</p></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Llopis</surname><given-names>M.</given-names></name><etal/></person-group><source>Gut</source><volume>65</volume><year>2016</year><fpage>830</fpage><lpage>839</lpage><pub-id pub-id-type="pmid">26642859</pub-id>
</element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Blanco-M&#x000ed;guez</surname><given-names>A.</given-names></name><etal/></person-group><source>Nat Biotechnol</source><volume>41</volume><year>2023</year><fpage>1633</fpage><lpage>1644</lpage><pub-id pub-id-type="pmid">36823356</pub-id>
</element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Mallick</surname><given-names>H.</given-names></name><etal/></person-group><source>PLoS Comput Biol</source><volume>17</volume><year>2021</year><object-id pub-id-type="publisher-id">e1009442</object-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Gastrointest</article-title><source>Tumors</source><volume>2</volume><year>2015</year><fpage>33</fpage><lpage>40</lpage></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N.</given-names></name><etal/></person-group><source>J&#x000a0;Immunol Res</source><year>2021</year><object-id pub-id-type="publisher-id">e4973589</object-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Berbert</surname><given-names>L.</given-names></name><etal/></person-group><source>Braz J Med Biol Res</source><volume>55</volume><year>2022</year><object-id pub-id-type="publisher-id">e11832</object-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Zaidi</surname><given-names>A.H.</given-names></name><etal/></person-group><source>Br J Cancer</source><volume>127</volume><year>2022</year><fpage>2016</fpage><lpage>2024</lpage><pub-id pub-id-type="pmid">36097175</pub-id>
</element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>M.</given-names></name><etal/></person-group><source>Microbiol Spectr</source><volume>12</volume><year>2024</year><object-id pub-id-type="publisher-id">e04012-23</object-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>M.C.</given-names></name><etal/></person-group><source>Nat Med</source><volume>27</volume><year>2021</year><fpage>1432</fpage><lpage>1441</lpage><pub-id pub-id-type="pmid">34239137</pub-id>
</element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>S.W.</given-names></name><etal/></person-group><source>Arch Microbiol</source><volume>206</volume><year>2023</year><fpage>19</fpage><pub-id pub-id-type="pmid">38086977</pub-id>
</element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgments:</title><p id="p0035">We address our gratitude to the different individuals that permitted this research, starting with the patient that accepted to join the CHIEF cohort and their relatives. We extend our thanks to the hepato-gastroenterology department of the Hospital University of Amiens, directed by the Pr. Nguyen-Khac, for overseeing the patient recruitment. In addition, we thank Mr Ducourneau and Pr. Ganry for allowing the access to the CHIEF faecal collection. Our appreciation extends to Dr Herpe of the Picardie Biobank for overseeing the storage of the samples. Lastly, we acknowledge the significant contributions of Dr Jedraszac, Mr. Herent, and Ms. Desjeux from the Genetics department of the Amiens University Hospital for their expertise in sequencing.</p></ack><fn-group><fn id="d36e26"><p id="ntpara0010"><bold>Conflicts of Interest:</bold> The authors disclose no conflicts.</p></fn><fn id="d36e30"><p id="ntpara0015"><bold>Funding:</bold> Damien Esparteiro is the recipient of a doctoral grant attributed by the &#x0201c;Region Haut-de-France&#x0201d;. Ano&#x000ef;sia Courtois is the recipient of a doctoral grant attributed by the Amiens University Hospital and the &#x0201c;Minist&#x000e8;re de l&#x02019;Enseignement Sup&#x000e9;rieur, de la Recherche et de l&#x02019;Innovation&#x0201c; (MESRI). The &#x0201c;Institut National du Cancer&#x0201d; (INCa) and &#x0201c;Institut pour la Recherche en Sant&#x000e9; Publique&#x0201d; (IReSP) call to research projects to reduce and fight against psychoactive substances consumption and addictions grant of 2021 financed Dr Gr&#x000e9;gory Fouquet&#x02019;s contribution and this investigation.</p></fn><fn id="d36e34"><p id="ntpara0020"><bold>Ethical Statement:</bold> The corresponding author, on behalf of all authors, jointly and severally, certifies that their institution has approved the protocol for any investigation involving humans and that all experimentation was conducted in conformity with ethical and humane principles of research. The fecal samples were obtained from the &#x0201c;Biobanque de Picardie&#x0201d;, at Amiens, after obtaining the explicit authorization from the direction of the CHIEF cohort. Due to the retrospective nature of this research, no registration at the institutional review board was required. The clinical trial number of the CHIEF cohort is NCT04348838, registered with the number 19.04.15.41412 by the &#x0201c;Comit&#x000e9; de Protection des Personnes Sud-Est IV&#x0201d; (RCB ID: 2019-A00679-48, PI2019_843_0023).</p></fn><fn id="d36e38"><p id="ntpara0025"><bold>Data Transparency Statement:</bold> The sequencing files and the associated metadata are publicly available under the BioProject accession number PRJNA1111312.</p></fn><fn id="d36e42"><p id="ntpara0030"><bold>Reporting Guidelines:</bold> None.</p></fn></fn-group></back></article>